Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
Jump to navigation
Jump to search
(→ILAE Classification: kosm) |
m (2014 rfz) |
||
Line 7: | Line 7: | ||
It is difficult to distinguish between genetic and cryptogenic syndromes. | It is difficult to distinguish between genetic and cryptogenic syndromes. | ||
Morbility data is difficult to interpret when WHO<ref>http://www.who.int/en/</ref> states 50 millions persons suffers '''epilepsy'''<ref>(Chung 2015)</ref> | Morbility data is difficult to interpret when WHO<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref> | ||
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref> | nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref> |
Revision as of 22:51, 25 July 2015
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih AED[5]
Medicines | ||||
type | ,,, | ,,,, | ||
INN | Generic | slow release | ||
carbamazepine | normal | xr | ||
lamotrigine | normal | xr | ||
levetiracetam | normal | xr | ||
oxcarbazepine | ... | xr | ||
phenitoin | ... | xr | ||
valproate | xr | |||
topiramate | xr | |||
AED |
ILAE Classification
See also
A new perspective for Epileptic Disorders
Links
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
References: |
|